160 related articles for article (PubMed ID: 21233484)
1. Sarcoidosis complicating treatment with natalizumab for Crohn's disease.
Parisinos CA; Lees CW; Wallace WA; Satsangi J
Thorax; 2011 Dec; 66(12):1109-10. PubMed ID: 21233484
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
Ghosh S
Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
6. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab: overview of its pharmacology and safety.
Baker DE
Rev Gastroenterol Disord; 2007; 7(1):38-46. PubMed ID: 17392628
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
[TBL] [Abstract][Full Text] [Related]
10. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for active Crohn's disease.
Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
[TBL] [Abstract][Full Text] [Related]
13. Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect.
Kotze PG; de Barcelos IF; da Silva Kotze LM
J Crohns Colitis; 2013 Dec; 7(11):e599-600. PubMed ID: 23849401
[No Abstract] [Full Text] [Related]
14. Natalizumab and HSV meningitis.
Shenoy ES; Mylonakis E; Hurtado RM; Venna N
J Neurovirol; 2011 Jun; 17(3):288-90. PubMed ID: 21487835
[TBL] [Abstract][Full Text] [Related]
15. Crohn's targeted therapy: myth or real goal?
Schmidt KJ; Büning J; Jankowiak C; Lehnert H; Fellermann K
Curr Drug Discov Technol; 2009 Dec; 6(4):290-8. PubMed ID: 20025597
[TBL] [Abstract][Full Text] [Related]
16. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease.
Sakuraba A; Annunziata ML; Cohen RD; Hanauer SB; Rubin DT
Inflamm Bowel Dis; 2013 Nov; 19(12):2577-83. PubMed ID: 24132161
[TBL] [Abstract][Full Text] [Related]
17. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab (Tysabri) for Crohn's disease.
Med Lett Drugs Ther; 2008 May; 50(1285):34-6. PubMed ID: 18458669
[No Abstract] [Full Text] [Related]
19. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
D'Haens G; Vermeire S; Vogelsang H; Allez M; Desreumaux P; Van Gossum A; Sandborn WJ; Baumgart DC; Ransohoff RM; Comer GM; Ahmad A; Cataldi F; Cheng J; Clare R; Gorelick KJ; Kaminski A; Pradhan V; Rivers S; Sikpi MO; Zhang Y; Hassan-Zahraee M; Reinisch W; Stuve O
J Crohns Colitis; 2018 Jan; 12(2):188-196. PubMed ID: 28961770
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
